It is made available under a CC-BY 4.0 International license .

1 Best practices of multi-ancestry, meta-analytic transcriptome-wide association studies: lessons

2 from the Global Biobank Meta-analysis Initiative

- 3
- 4 Arjun Bhattacharya^{*1,2}, Jibril B. Hirbo^{*3,4}, Dan Zhou^{3,4}, Wei Zhou^{5,6,7}, Jie Zheng⁸, Masahiro Kanai^{5,6,7,9,10},
- the Global Biobank Meta-analysis Initiative, Mark J. Daly^{5,6,7,11}, Bogdan Pasaniuc^{1,8,9+}, Eric R.
- 6 Gamazon^{3,4,14+}, Nancy J. Cox^{3,4+}
- 7
- Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, United States
- Institute of Quantitative and Computational Biosciences, David Geffen School of Medicine, University
 of California, Los Angeles, CA, United States
- Department of Medicine, Division of Genetic Medicine, Vanderbilt University School of Medicine, Nashville, TN, United States
- 4. Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, TN, United States
- 5. Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA
- 16 6. Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA
- 17 7. Stanley Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge, MA
- MRC Integrative Epidemiology Unit (IEU), Bristol Medical School, University of Bristol, Oakfield
 House, Oakfield Grove, Bristol, BS8 2BN, UK
- 9. Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA
- Department of Statistical Genetics, Osaka University Graduate School of Medicine, Suita 565-0871,
 Japan
- 11. Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland
- 12. Department of Human Genetics, David Geffen School of Medicine, University of California, Los
 Angeles, CA, United States
- 13. Department of Computational Medicine, David Geffen School of Medicine, University of California,
 Los Angeles, CA, United States
- 14. MRC Epidemiology Unit, University of Cambridge, Cambridge, UK
- 29 *Corresponding authors: Arjun Bhattacharya (<u>abtbhatt@ucla.edu</u>), Jibril Hirbo (jibril.hirbo@vumc.org)
- ³⁰ ⁺These authors contributed equally to this manuscript.

It is made available under a CC-BY 4.0 International license .

31 SUMMARY

The Global Biobank Meta-analysis Initiative (GBMI), through its genetic and demographic diversity, 32 provides a valuable opportunity to study population-wide and ancestry-specific genetic associations. 33 However, with multiple ascertainment strategies and multi-ethnic study populations across biobanks, the 34 GBMI provides a distinct set of challenges in implementing statistical genetics methods. Transcriptome-35 wide association studies (TWAS) are a popular tool to boost detection power for and provide biological 36 37 context to genetic associations by integrating single nucleotide polymorphism to trait (SNP-trait) associations from genome-wide association studies (GWAS) with SNP-based predictive models of gene 38 39 expression. TWAS presents unique challenges beyond GWAS, especially in a multi-biobank and metaanalytic setting like the GBMI. In this work, we present the GBMI TWAS pipeline, outlining practical 40 considerations for ancestry and tissue specificity and meta-analytic strategies, as well as open challenges 41 at every step of the framework. Our work provides a strong foundation for adding tissue-specific gene 42 expression context to biobank-linked genetic association studies, allowing for ancestry-aware discovery to 43 44 accelerate genomic medicine.

45

46 KEYWORDS

transcriptome-wide association study; meta-analysis; multi-ancestry genetic analysis; Global Biobank
Meta-analysis Initiative

49

50 INTRODUCTION

51 Large population-based or clinical-case based biobanks are a key component of precision medicine

efforts and provide opportunities for genetic and genomic research (Abul-Husn and Kenny, 2019).

- 53 Biobanks offer context to deploy genome-wide associations (GWAS) at scale. Multi-biobank
- collaborations facilitate well-powered, multi-ethnic genetic research (Swede et al., 2007). In addition, such
- collaborations can accelerate the elucidation of the biological mechanisms that underlie diseases by in-

silico longitudinal genetic studies and examination of pleiotropy.

It is made available under a CC-BY 4.0 International license .

A key challenge in GWAS is interpreting significant trait-associated loci and these loci to genes or 58 epigenomic features (Gallagher and Chen-Plotkin, 2018; Wijmenga and Zhernakova, 2018). Viable 59 options to add biological interpretation to our understanding of GWAS loci include colocalization 60 (Giambartolomei et al., 2014, 2018; Gleason et al., 2020; He et al., 2013) or Mendelian randomization 61 methods (Hauberg et al., 2017; Pavlides et al., 2016; Smith and Ebrahim, 2003). Another suite of tools 62 include transcriptome-wide association studies (TWAS), which integrate GWAS with expression 63 64 quantitative trait loci (eQTL) analyses to prioritize gene-trait associations (GTAs) with applications of mediation analysis (Gamazon et al., 2015; Gusev et al., 2016) or Mendelian randomization (Zhang et al., 65 66 2020). TWAS involves three general steps. First, per-gene predictive models of gene expression are trained in the eQTL dataset using genetic variants. Then, genetically-regulated expression (GReX) is 67 imputed in the GWAS cohort with individual-level genotypes. Lastly, statistical associations between 68 GReX and trait are estimated (Barbeira et al., 2018; Gamazon et al., 2015; Gusev et al., 2016). TWAS is 69 also viable with GWAS summary statistics by estimating the test statistic of the TWAS association using a 70 71 proper LD reference panel (Gusev et al., 2016). Generally, most TWAS methods predict expression using 72 SNPs local to the gene within 1 Megabase of the gene body (Barbeira et al., 2018; Gamazon et al., 2015; 73 Gusev et al., 2016; Hu et al., 2019; Nagpal et al., 2019; Zhou et al., 2020). Recently, methods that include strong distal-eQTL signals have shown improved prediction and power to detect GTAs (Bhattacharya et 74 al., 2021a; Luningham et al., 2020). Nonetheless, practical and statistical considerations to accurately 75 prioritize GTAs through TWAS still require methodological improvement. 76

77

Along with those from traditional GWAS, TWAS introduces new challenges by incorporating gene 78 expression (Wainberg et al., 2019) (Figure 1A). On the genetic level, as in GWAS, disentangling signals 79 from complex LD structure, relatedness, and ancestry requires careful modeling considerations 80 (Mbatchou et al., 2020; Zhou et al., 2018). Selection of LD reference is specifically important in multi-81 ancestry settings, like the GBMI, as LD structure across ancestry groups differs greatly(Shifman et al., 82 2003). Mismatched LD may lead to gene expression models with reduced predictive power, reduced 83 power to detect GTAs, and increased false positives (Bhattacharya et al., 2020; Geoffroy et al., 2020; 84 85 Keys et al., 2020). In addition, phenotype acquisition and aggregation are challenging, especially across

It is made available under a CC-BY 4.0 International license .

multiple biobanks with different healthcare, electronic health record, and case-control definitions.
However, compared to GWAS, a challenge specific to TWAS is the integration of gene expression with
GWAS signal. Not only is it an active topic of methodological research to choose an optimal set of genes
and tissues that best explains the phenotype association at a given genetic locus, the role of contextspecific expression is still being evaluated in trait associations. Dynamic differences in bulk tissue
expression from cell-type- or cell-state-specificity can give additional granularity to gene-trait associations.
The impact of these challenges in a meta-analytic framework has not been previously explored.

Here, we outline a framework for analyzing trans-ancestry, meta-analytic GWAS across multiple biobanks
with TWAS. We review and explore practical considerations for all three steps (Figure 1B): ancestry
specificity of expression models and LD reference panels, meta-analytic techniques for detection of
GTAs, and follow-up tests and analyses for biological context. Our framework can be applied to various
phenotypes to study population-wide and ancestry-specific genetic associations mediated by tissuespecific expression.

100

101 **RESULTS**

102 Expression models are not portable across ancestry groups

The diversity represented in the GBMI enables uniquely well-powered studies to detect genetic 103 associations in non-European populations. However, optimal TWAS requires ancestry-matched training 104 datasets of genetic and tissue-specific gene expression data, which are still lacking in non-European 105 samples. As Cao et al points out (Cao et al., 2021), statistical power to detect GTAs in TWAS is 106 107 dependent on expression heritability and the ability of the predictive expression model to recapitulate that heritable expression in the external GWAS panel. Accordingly, training expression models that perform 108 well in all ancestry populations is necessary to ensure that discoveries made through TWAS are not 109 restricted to European populations. For the first GBMI TWAS, we restrict analysis to populations of 110 European ancestry, due to small sample sizes of non-European ancestry samples (Aguet et al., 2020). 111 However, as sample sizes for eQTL datasets in non-European populations increase, the TWAS pipeline 112

It is made available under a CC-BY 4.0 International license .

113 will include expression models for these understudied and underserved populations (STAR Methods).

Here, we illustrate some challenges in building these expression models across ancestry groups.

115

We considered the 5 tissues in GTEx with at least 70 samples from both European (EUR) and African 116 (AFR) ancestry: subcutaneous adipose (abbreviated ADIP, N = 71 samples of AFR ancestry and 492 117 samples of EUR ancestry), tibial artery (ARTERY, N = 76 and 489), skeletal muscle (MUSC, N = 86 and 118 602), sun exposed lower leg skin (SKIN, N = 73 and 518), and whole blood (BLOOD, N = 80 and 574). 119 120 For genes with significantly heritable expression in both EUR and AFR GTEx samples (restricted maximum likelihood-based estimate of heritability > 0 with nominal P < 0.01, we trained EUR- and AFR-121 specific models using elastic net regularized regression (Friedman et al., 2010) and imputed expression 122 into the aligned (i.e., training and imputation samples have similar ancestries) and misaligned (i.e., 123 training and imputation sample have different ancestries). For context, we also built ancestry-unaware 124 125 models, where EUR and AFR samples were pooled together. We calculated predictive performance with adjusted R² to account for sample size, using leave-one-out CV when measuring predicting performance 126 in an aligned imputation sample (STAR Methods). 127

128

Across these tissues, models trained in EUR samples performed, on average, 4 times worse (differences 129 of 0.03-0.04 in median adjusted R²) in AFR samples compared to models trained in AFR samples (Figure 130 2A, Tables S1-S3), with more than 80% of gene models with stronger performance if trained in AFR 131 samples. Similar trends hold for ancestry-specific models imputed into down-sampled EUR imputation 132 samples (Figure S1-S2, Table S1-S3), consistent with previous simulation and real-world studies 133 (Bhattacharya et al., 2020; Keys et al., 2020); here, we considered a randomly selected EUR imputation 134 sample with equal sample size to that of the AFR sample in the same tissue. In fact, we observed that 135 ancestry-specific models imputed into a sample with aligned ancestry showed larger predictive R² than 136 ancestry-unaware (individuals of EUR and AFR ancestry in the training sample) models imputed into the 137 same sample (Figure 2B, Table S4), despite generally increased sample sizes. This observation also 138 holds if we further increase the sample size of the training sample by including individuals of other 139 ancestries (Asian, American Indian, and Unknown ancestries) into the training sample (Figure S3). This 140

It is made available under a CC-BY 4.0 International license .

observation emphasizes the need for ancestry matching in gene prediction from genetic data and greater
 recruitment of non-European ancestry patients in eQTL studies.

143

In these analyses, one reason ancestry-unaware models may perform poorly in AFR samples is due to 144 differences in minor allele frequency (MAF) of highly predictive SNPs between EUR and AFR ancestry 145 populations. It is important to note that this discrepancy is not generally specific to any one ancestry; 146 147 rather, ancestry imbalance in the training or reference datasets may lead to poor portability of genetic models due to differences in allele frequency. To account for common SNPs in both AFR or EUR 148 ancestry populations, we additionally trained ancestry-unaware and ancestry-specific models using SNPs 149 with minor allele frequency (MAF) exceeding various thresholds in both AFR and EUR samples. 150 Excluding SNPs with MAF < 0.01 improved predictive performance of ancestry-unaware models across 151 all tissues (Figure S4, Table S5). However, the gap in predictive performance between ancestry-specific 152 and ancestry-unaware models did not decrease when the MAF cutoff was increased (Figure 2B, Table 153 154 **S4**). This observation may reflect that dropping ancestry-specific rarer SNPs ignores variants with large ancestry-specific effects on gene expression. Additionally, excluding rare ancestry-specific SNPs does 155 not address the differences in LD across the EUR and AFR samples which leads to different 156 regularization paths and, hence, SNP-gene weights. Addressing the trans-ancestry portability of 157 expression models remains an open study direction; methodology that borrows information from 158 functional annotations or across different cell-type- or cell-state-specific contexts may bridge this gap in 159 predictive performance, similar to recent developments in polygenic risk score prediction for complex 160 traits (Amariuta et al., 2020; Márquez-Luna et al., 2020). 161

162

163 Meta-analytic strategies must be ancestry-aware

Another critical consideration for the GBMI involves meta-analysis while using GWAS summary statistics. TWAS estimates the association between GReX and the phenotype by weighting the standardized SNPtrait effect sizes from GWAS summary statistics by SNP-gene weights from the expression models. To account for the correlation between SNPs, an external LD reference panel, like the 1000Genomes Project (Auton et al., 2015), is used to estimate the standard error of the TWAS association. Accordingly, the

It is made available under a CC-BY 4.0 International license .

accuracy of this reference panel to the LD structure in the GWAS cohort dictates how aligned the 169 summary-statistics based TWAS association is to the TWAS association from direct imputation into 170 individual-level genotypes in the GWAS cohort. Ideally, in-sample LD will give the best estimate of the 171 TWAS standard error, but several biobanks do not provide this information under their specific genetic 172 data sharing and privacy policies. Even departures in LD across subgroups of European ancestry 173 populations may influence the standard error estimate. In addition, as the estimates of SNP-gene weights 174 175 are influenced by the LD in the eQTL panel, differences in LD between the eQTL and GWAS panel will also affect the TWAS effect size. 176

177

As LD structure greatly differs across ancestry groups (Shifman et al., 2003), pooling ancestry groups in 178 TWAS may lead to reduced power. We conducted TWAS for asthma risk using ancestry-unaware and 179 EUR- and AFR-specific models of whole blood expression (4,782 genes with heritable expression at 180 nominal P < 0.01 and models with cross-validation $R^2 > 0.01$ with nominal P < 0.05, trained via elastic net 181 regression). Ancestry-specific TWAS Z-scores across EUR and AFR ancestry groups were not strongly 182 183 correlated (r = 0.11), potentially due to differences in sample size and eQTL and GWAS architecture (Figure 3A, Figure S5-S6) (Shang et al., 2020; Wyss et al., 2018). In fact, we detected only two genes 184 across both EUR and AFR with P < 2.5×10^{-6} . One of these genes. *DFFA*, has been implicated with 185 186 asthma risk through GWAS and colocalization in EUR (Vicente et al., 2017). However, the TWAS associations across EUR and AFR were in opposite directions using blood tissue. In the other 4 tissues 187 explored, DFFA TWAS associations did not reach transcriptome-wide significance but effect directions 188 were generally concordant (Figure S7). In blood, lead local-eQTLs (within 1 Megabase) of DFFA show 189 are in opposite directions, though only nominally significant at P < 0.05 (Figure S8). Although they are 190 within 60 kilobases, the lead eQTLs for DFFA across AFR (rs263526) and EUR (rs903916) are not in LD 191 $(R^2 = 3 \times 10^{-4} \text{ in AFR}, 0.0072 \text{ in EUR})$. The GWAS effect sizes of SNPs local to DFFA do not show large 192 193 deviations in effect direction and are only nominally significant, as well (Figure S8). These differences in TWAS associations across ancestry motivate careful consideration of meta-analytic strategy to avoid 194 biasing cross-ancestry associations towards cohorts with larger sample sizes, which still tend to be 195 196 predominantly of EUR ancestry.

It is made available under a CC-BY 4.0 International license .

197

We investigated 5 different meta-analytic strategies empirically: meta-analyzing across ancestry-specific, 198 per-biobank GWAS summary statistics using (1) inverse-variance weighting (IVW) and (2) sample-size 199 weighting (SSW), meta-analyzing across ancestry-specific meta-analyzed GWAS summary statistics 200 using (3) IVW and (4) SSW, and (5) TWAS using ancestry-unaware models and meta-analyzed GWAS 201 summary statistics across EUR and AFR ancestry groups (STAR Methods). QQ-plots in Figure 3B show 202 203 earlier departure of Z-scores from the QQ-line for SSW meta-analyzed Z-scores and the ancestryunaware strategy, suggesting inflation. This observation is supported with estimates of test statistic bias 204 205 and inflation using an empirical Bayes method, bacon (van Iterson et al., 2017), which show the largest estimated bias and inflation for these SSW and ancestry-unaware methods. IVW strategies show similar 206 levels of inflation, with IVW meta-analysis across ancestry-specific meta-analyzed GWAS summary 207 statistics showing minimal bias (Figure S9). These results align with intuition - that the more naïve SSW 208 meta-analysis and ancestry-unaware methods bias towards EUR cohorts, which have the larger sample 209 210 sizes, whereas Z-scores from the IVW methods showed positive correlations with Z-scores from AFR cohorts (Figure S6). 211

212

However, it is unclear whether ancestry-specific IVW meta-analysis to the per-biobank level is necessary. 213 As shown in **Figure S10**, Z-scores from these two IVW methods are moderately positively correlated (r =214 215 0.51 across 4,152 Z-scores), with this correlation increasing when we consider genes with nominally significant Z-scores for both strategies (r = 0.70 across 564 tests). We observed that top associations 216 across these IVW meta-analyses often had high degrees of heterogeneity in effect size across biobanks, 217 as measured by the Higgins-Thompson I² statistic (Figure 3C, Figure S11) (Higgins and Thompson, 218 2002). One gene, A1BG, that showed directionally concordant transcriptome-wide significant associations 219 across both IVW strategies had a large degree of heterogeneity in the underlying participating cohorts (I² 220 = 0.77). In fact, the cross-biobank heterogeneity is often larger than the cross-ancestry heterogeneity for 221 TWAS associations of A1BG. Interestingly, ZNF665, another gene with directionally concordant 222 223 associations across both IVW strategies showed a low degree of heterogeneity in the per-biobank effect 224 sizes ($l^2 = 0.26$). However, genes with discordant associations across IVW strategies showed varied

It is made available under a CC-BY 4.0 International license .

225 patterns. Two illustrative examples are MLNR and MYOZ3, both with large degrees of test statistic heterogeneity ($I^2 = 0.91$ and 0.82, respectively). Across the two IVW strategies, effect sizes are in 226 opposite directions, possibly due to large standard error differences across the ancestry-specific per-227 biobank associations. A thorough investigation of the power and false discovery rates of these meta-228 analysis strategies through simulations is necessary. More sophisticated methods (Hedges and Vevea, 229 1998; Lee et al., 2017; Shi and Lee, 2016) that can properly incorporate the per-biobank uncertainty into 230 231 meta-analyzed TWAS associations must be explored to increase power and properly leverage the large sample sizes of the GBMI. 232

233

In addition to considerations for TWAS in trans-ethnic populations, analyzing genetic data from individuals 234 of admixed ancestry is also an open area of study. For example, in this analysis, we have used the 235 1000Genomes AFR LD reference panel as an estimate of the LD for the AFR-ancestry samples from 236 each biobank. However, most of these AFR-ancestry populations are of admixed ancestry (e.g. African 237 238 Americans or African British). A single LD reference panel of AFR-ancestry may not reflect the genetic 239 diversity in these admixed populations of AFR and EUR ancestries from around the world (Baharian et al., 2016). As Zhong et al highlights, in multiethnic and admixed populations, using local ancestry 240 estimates aids in better characterization of heritability of complex traits and more accurate mapping of 241 genetic associations, especially eQTLs (Zhong et al., 2019). Accordingly, incorporating local ancestry 242 estimates into both expression model step and the association testing step of TWAS may lead to 243 increased power and should be explored. 244

245

246 Follow-up tests provide biological and clinical context to TWAS GTAs

TWAS GTAs identified using GWAS summary statistics are subject to several factors that may lead to false positives. We implement several follow-up tests to provide context to TWAS-identified GTAs. First, a TWAS GTA could attain transcriptome-wide significance due to only the strong SNP-trait associations from the underlying GWAS. To quantify the significance of the GTA conditional on the SNP-trait effects at the locus, we perform a permutation test by permuting the SNP-gene weights from the expression model to generate a null distribution (**STAR Methods**). Comparing the original TWAS Z-score to this null

It is made available under a CC-BY 4.0 International license .

distribution assesses how much signal is added by the expression given the specific GWAS architecture
of the locus. As Gusev *et al* point out, this permutation test is highly conservative and intended to
prioritize only associations already significant in the standard TWAS GTA detection (Gusev et al., 2016).

Next, gene expression models for genes in adjacent genomic windows may be built from overlapping 257 SNPs or SNPs in strong LD. When TWAS detects GTAs in overlapping genomic regions, we apply 258 259 Bavesian probabilistic fine-mapping using FOCUS (Mancuso et al., 2019) to estimate a 90% credible set of genes to explain the observed association signal in a given tissue (STAR Methods). However, the 260 261 current iteration of FOCUS has limitations. Priors for the correlation matrix between GReX of overlapping genes are dependent on SNP LD reference panels. Thus, fine-mapping in trans-ancestry settings is 262 difficult, though recent machinery has been added to FOCUS to account for differences in genetic 263 architecture across the study sample (Gopalan and Lu et al, in preparation). Another challenge for gene-264 level fine-mapping in multi-tissue TWAS is distinguishing between overlapping signals across tissues. 265 Primarily due to cross-cell-type variation in expression levels and eQTL architecture, TWAS may prioritize 266 267 genes in multiple tissues that are overrepresented by the same underlying causal cell-types (Wainberg et 268 al., 2019). This multi-tissue gene prioritization extends to fine-mapping overlapping TWAS signals across tissue, as priors for FOCUS are not tissue-dependent. An interesting future direction involves careful 269 tissue-specific prior elicitation in TWAS fine-mapping – extracting posterior signal that is biologically 270 consistent and meaningful without allowing the prior to dominate. 271

272

The GBMI TWAS model incorporates gene expression models using MOSTWAS, a TWAS extension that 273 274 prioritizes distal-eQTLs by testing their mediation effect through local molecular features (STAR 275 Methods). For genes with models trained with MOSTWAS and associated with the trait at transcriptomewide significance, we test the additional association signal from the distal-SNPs using an added-last test, 276 277 analogous to a group-added-last test in linear regression (Bhattacharya et al., 2021a). This test also prioritizes sets of genomic or epigenomic features that mediate the predicted distal-eQTLs for subsequent 278 279 study of upstream, tissue-specific regulation of GTAs. In one application of MOSTWAS, one prioritized functional hypothesis was experimentally validated in vitro (Bhattacharya et al., 2021b). As distal-eQTLs 280

It is made available under a CC-BY 4.0 International license .

are more likely to be tissue- or cell-type-specific (Yang et al., 2017), the association signal from these
 distal-eQTLs could also be leveraged in cross-tissue fine-mapping strategies.

283

Lastly, TWAS suffers from severely reduced power and inflated false positives in the presence of SNP 284 pleiotropy, where the genetic variants in the gene expression model affect the trait, independent of gene 285 expression (Veturi and Ritchie, 2018). We encourage estimating the degree of and accounting for SNP 286 287 pleiotropy using LDA-MR-Egger (Barfield et al., 2018) or PMR-Egger (Yuan et al., 2020), especially in settings with individual-level GWAS genotypes. Applications for these methods using GWAS summary 288 289 statistics reveals some inflation of standard errors (Zhu et al., 2021), suggesting the need for further evaluation and development of summary statistics-based methods to account for SNP pleiotropy in 290 TWAS GTA detection. 291

292

293 Biobanks enable GReX-PheWAS for biological context

294 Biobanks aggregated in the GBMI provide a rich catalog of phenotypes for analysis, with phenotype 295 codes (phecodes) aggregated from ICD codes classified into clinically relevant categories (Wei et al., 296 2017). This phenotype catalog enables Phenome-Wide Association Studies (PheWAS) as a complement to GWAS by both replicating GWAS associations and providing a larger set of traits associations with 297 GWAS variants. To follow-up on novel TWAS-prioritized genes, we may expand the PheWAS framework 298 to the tissue-specific GReX level in a similarly complementary analysis: GReX-level Phenome-Wide 299 Association Study (GReX-PheWAS), as previously deployed in biobank settings and similar to the 300 PredixVU database (Pathak et al., 2020; Unlu et al., 2019, 2020). Not only do these analyses replicate 301 302 and detect new TWAS associations, but they can also point to groups of phenotypes that show 303 enrichments for trait-associations for the gene of interest.

304

305 We briefly illustrate an example of GReX-PheWAS using 3 genes (Figure 4, Figure S12-S13, Table S6):

306 *TAF7*, a novel gene in our TWAS, and *ILRAP18* and *TMEM258*, two genes previously implicated through

307 GWAS (Johansson et al., 2019; Portelli et al., 2020; Reijmerink et al., 2008, 2010; Zhu et al., 2020).

308 These genes were prioritized from European-specific TWAS for asthma risk from Zhou et al (Zhou et al.,

It is made available under a CC-BY 4.0 International license .

309 2021) using lung tissue expression (101,311 cases and 1,118,682 controls): TAF7 (MOSTWAS model), IL18RAP (JTI model), and TMEM258 (JTI model). European-specific TWAS meta-analysis for asthma 310 detected a negative association with TAF7 cis-GReX, a gene that did not intersect a GWAS-significant 311 locus. In TWAS follow-up tests, TAF7 passed permutation testing and was estimated in the 90% credible 312 set at the genomic locus via FOCUS with posterior inclusion probability 1. TAF7 encodes a component of 313 the TFIID protein complex, which binds to the TATA box in class II promoters and recruits RNA 314 315 polymerase II and other factors (Bhattacharva et al., 2014). As the clinically-relevant associations for TAF7 lung GReX are not characterized, we employed GReX-PheWAS in UKBB European-ancestry 316 317 GWAS summary statistics across 731 traits and diseases with sample sizes greater than 100,000, grouped into 9 categories (Figure 4, STAR Methods). We see enrichments for phenotypes of the 318 hematopoietic and musculoskeletal groups (Figure 4A) with hypothyroidism and chronic laryngitis as the 319 top phenotype associations (Figure 4B, Table S6). These phenotypes include multiple inflammations of 320 organs (e.g., laryngitis, osteitis, meningitis, inflammations of the digestive and respiratory system, etc). 321 322 We also detected several associations with related respiratory diseases and traits. Similarly, for the two 323 previously implicated genes, we find enrichments for respiratory and hematopoietic GTAs for ILRAP18 and across multiple categories for TMEM258, consistent with the categorized functions and associations 324 of these genes (Figure S12-S13, Table S6). The utility of GBMI's robust roster of phenotypes enables 325 GReX-PheWAS to add biological and clinical context to novel TWAS associations. 326

327

GReX-PheWAS, despite its utility, shares the challenges of PheWAS. Phenotypes within and across 328 groups may be correlated, leading to a series of dependent tests. Even divergent phenotypes may be 329 330 correlated, either clinically or biologically. Thus, simple adjustments of multiple testing burden may not be appropriate, and methods that account for correlation between phenotypes, like permutation tests, may 331 be more applicable (Hebbring, 2014; Korthauer et al., 2019; Stevens et al., 2017; Wei et al., 2017). In 332 addition, covariate adjustments in expression models built for disease-specific analyses may not be 333 generalizable for multiple phenotypes. Most population-based clinical biobanks lack comprehensive 334 clinical and lifestyle information of the individuals. Phenotyping information is typically incomplete, mostly 335 336 due to gaps in electronic health records. Phenotype groupings may also be deceptive: as most biobanks

It is made available under a CC-BY 4.0 International license .

follow ICD coding that groups traits and diseases by body systems, GReX-PheWAS enrichments for a 337 given group may not reflect shared genetic pathways across body systems. In addition, case-control 338 selection may not be optimal due to differences in exclusion criteria (McGuirl et al., 2020). Lastly, 339 phenotype acquisition and aggregation across multiple biobanks is challenging, with different healthcare, 340 electronic health record, and case-control definition assignments. Despite these limitations in phenotype 341 acquisition, recent methods focusing on identifying shared genetic architecture among multiple 342 343 phenotypes (McGuirl et al., 2020) in a phenome-wide approach highlight the advantages of GReX-PheWAS. 344

345

346 DISCUSSION

Here, we provide a framework for TWAS in a multi-biobank setting across many ancestry groups. Our 347 work outlines several methodological gaps that should be addressed in the future: (1) training expression 348 models that are portable across ancestry groups, (2) limiting false discovery in TWAS by properly 349 350 modeling differences in LD across ancestry groups, (3) incorporating uncertainty within and heterogeneity 351 across biobanks to boost TWAS meta-analytic power, and (4) contextualizing TWAS GTAs through follow-up testing, probabilistic fine-mapping across ancestry groups and expression contexts, and GReX-352 PheWAS. Along with the discussed issues with current TWAS methodology, tissue-specific expression 353 may not provide sufficient granularity needed to discover trait-relevant biological mechanisms. Recent 354 methods that study the mediation of the SNP-trait relationship by cell-type heterogeneity show that cell-355 types are influenced by genetics and predict complex traits (Liu et al., 2021). In turn, single-cell eQTL 356 datasets can be integrated with GWAS to identify cell-type- or cell-state-specific expression pathways that 357 358 are health- or disease-related. Incorporating single cell expression data into a predictive model will require more sophisticated statistical methodology that relies on modeling cell identity as a spectrum, 359 rather than a categorical definition (Burkhardt et al., 2021; Verma and Engelhardt, 2020). Furthermore, a 360 multi-omic approach that incorporates functional data with TWAS may better model the flow of biological 361 information in a biologically interpretable fashion (Baca et al., 2021; Bhattacharya et al., 2021a), with 362 Zhao et al, in preparation. 363

364

It is made available under a CC-BY 4.0 International license .

365	Despite the limitations of this suite of methods, TWAS continues to be a useful tool for interpreting GWAS
366	associations and independently discovering genetic associations mediated by gene expression. There is
367	a severe need for an increase in reference eQTL data from individuals of non-European ancestry at parity
368	with those of European-ancestry individuals. Moreover, more sophisticated integrative computational and
369	experimental tools to complement improved TWAS and GWAS to understand the biology underlying
370	health and disease need to be developed.
371	
372	FUNDING
373	BP was partially supported by NIH awards R01 HG009120, R01 MH115676, R01 CA251555, R01
374	AI153827, R01 HG006399, R01 CA244670, U01 HG011715. ERG is supported by the National Institutes
375	of Health (NIH) grants: NHGRI R35HG010718, NHGRI R01HG011138, NIA AG068026, and NIGMS
376	R01GM140287. NJC is supported by U01HG009086.
377	
378	DATA AND CODE AVAILABILITY
378 379	DATA AND CODE AVAILABILITY The all-biobank and ancestry-specific GWAS summary statistics are publicly available for downloading at
379	The all-biobank and ancestry-specific GWAS summary statistics are publicly available for downloading at
379 380	The all-biobank and ancestry-specific GWAS summary statistics are publicly available for downloading at https://www.globalbiobankmeta.org/resources and browsed at the PheWeb Browser
379 380 381	The all-biobank and ancestry-specific GWAS summary statistics are publicly available for downloading at https://www.globalbiobankmeta.org/resources and browsed at the PheWeb Browser https://results.globalbiobankmeta.org/resources and browsed at the PheWeb Browser
379 380 381 382	The all-biobank and ancestry-specific GWAS summary statistics are publicly available for downloading at https://www.globalbiobankmeta.org/resources and browsed at the PheWeb Browser https://results.globalbiobankmeta.org/ . 1000 Genome Phase 3 data can be accessed at http://results.globalbiobankmeta.org/ . 1000 Genome Phase 3 data can be accessed at http://results.globalbiobankmeta.org/ . 1000 Genome Phase 3 data can be accessed at http://ftp.1000genomes_project/data . MOSTWAS can
379 380 381 382 383	The all-biobank and ancestry-specific GWAS summary statistics are publicly available for downloading at https://www.globalbiobankmeta.org/resources and browsed at the PheWeb Browser http://results.globalbiobankmeta.org/. 1000 Genome Phase 3 data can be accessed at ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/data_collections/1000_genomes_project/data. MOSTWAS can be accessed from https://github.com/bhattacharya-a-bt/MOSTWAS, and JTI can be accessed from
379 380 381 382 383 383	The all-biobank and ancestry-specific GWAS summary statistics are publicly available for downloading at https://www.globalbiobankmeta.org/resources and browsed at the PheWeb Browser http://results.globalbiobankmeta.org/. 1000 Genome Phase 3 data can be accessed at ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/data_collections/1000_genomes_project/data. MOSTWAS can be accessed from https://github.com/bhattacharya-a-bt/MOSTWAS, and JTI can be accessed from https://github.com/gamazonlab/MR-JTI. Sample scripts for this manuscript are available at
379 380 381 382 383 384 385	The all-biobank and ancestry-specific GWAS summary statistics are publicly available for downloading at https://www.globalbiobankmeta.org/resources and browsed at the PheWeb Browser http://results.globalbiobankmeta.org/. 1000 Genome Phase 3 data can be accessed at ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/data_collections/1000_genomes_project/data. MOSTWAS can be accessed from https://github.com/bhattacharya-a-bt/MOSTWAS, and JTI can be accessed from https://github.com/gamazonlab/MR-JTI. Sample scripts for this manuscript are available at
379 380 381 382 383 384 385 386	The all-biobank and ancestry-specific GWAS summary statistics are publicly available for downloading at https://www.globalbiobankmeta.org/resources and browsed at the PheWeb Browser http://results.globalbiobankmeta.org/. 1000 Genome Phase 3 data can be accessed at ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/data_collections/1000_genomes_project/data. MOSTWAS can be accessed from https://github.com/bhattacharya-a-bt/MOSTWAS , and JTI can be accessed from https://github.com/bhattacharya-a-bt/MOSTWAS , and JTI can be accessed from https://github.com/bhattacharya-a-bt/MOSTWAS , and JTI can be accessed from https://github.com/bhattacharya-a-bt/MOSTWAS , and JTI can be accessed from https://github.com/bhattacharya-a-bt/MOSTWAS , and JTI can be accessed from https://github.com/bhattacharya-a-bt/gbmi_twas .
379 380 381 382 383 384 385 386 386	The all-biobank and ancestry-specific GWAS summary statistics are publicly available for downloading at https://www.globalbiobankmeta.org/resources and browsed at the PheWeb Browser http://results.globalbiobankmeta.org/. 1000 Genome Phase 3 data can be accessed at ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/data_collections/1000_genomes_project/data. MOSTWAS can be accessed from https://github.com/bhattacharya-a-bt/MOSTWAS, and JTI can be accessed from https://github.com/gamazonlab/MR-JTI. Sample scripts for this manuscript are available at https://github.com/bhattacharya-a-bt/gbmi_twas.

- ³⁹¹ effort. We would like to thank Daniel King from the Hail team and Sam Bryant from the Stanley Center
- 392 Data Management team at the Broad Institute for helping with the Google bucket set up and data

It is made available under a CC-BY 4.0 International license .

sharing, and Bethany Klunder from the University of Michigan Medical school for helping with the

- 394 paper submission.
- 395

396 AUTHOR CONTRIBUTIONS

- ³⁹⁷ Conceptualization: AB, JH; Methodology: AB, JH, DZ, ERG, BP, NJC; Software: AB, JH, DZ, ERG, BP,
- NJC; Validation: AB, JH, DZ; Formal analysis: AB, JH; Investigation: all authors; Resources: all authors;
- ³⁹⁹ Data curation: WZ, MK; Writing original draft: AB, JH; Writing Review & Editing: all authors;
- Visualization: AB, JH; Supervision: EG, BP, NJC; Project administration: AB, JH, ERG, BP, NJC; Funding
- 401 acquisition: all authors
- 402

403 DECLARATION OF INTERESTS

- 404 MJD is a founder of Maze Therapeutics. ERG receives an honorarium from the American Heart
- 405 Association, as a member of the Editorial Board of *Circulation Research*.
- 406

407 FIGURE LEGENDS

Figure 1: Overview of GBMI transcriptome-wide association study (TWAS) pipeline with challenges at 408 every data level. (A) Each level of data in TWAS introduces a unique set of challenges: (1) genetics data 409 include confounding from genetic ancestry, population structure and relatedness, and complex linkage 410 disequilibrium patterns, (2) gene expression data introduces context-specific factors, such as tissue-, cell-411 type-, or cell-state-specific expression, and (3) phenotypic data, especially in the meta-analyses of 412 413 multiple biobanks, involve challenges in acquiring and aggregating phenotypes, properly defining controls 414 for phenotypes, and ascertainment and selection bias from non-random sampling. (B) An overview of the GBMI TWAS pipeline: (1) JTI and MOSTWAS for model training, (2) inverse-variance weighted meta-415 analysis using per-biobank, per-ancestry group TWAS summary statistics, and (3) various follow-up tests, 416 including conditional or permutation tests, distal-SNPs added last test, probabilistic fine-mapping using 417 FOCUS, and tests for SNP horizontal pleiotropy. Dotted lines represent associations that are tested in the 418 TWAS pipeline, while the solid lines represent a link built through predictive modeling. 419

420

It is made available under a CC-BY 4.0 International license .

Figure 2: Comparison of predictive performance of genetic models of expression across ancestry. (A) Distribution of difference in adjusted R² (Y-axis) when predicting expression in the AFR imputation sample between models trained in EUR and in AFR training samples across tissue (X-axis). (B) Distribution of difference in adjusted R² between ancestry-specific and ancestry-unaware models imputing into EUR (left) and AFR (right) samples.

426

427 Figure 3: Comparison of meta-analytic strategies for multi-biobank, trans-ancestry TWAS. (A) Scatterplot of per-ancestry meta-analyzed TWAS scores across EUR (X-axis) and AFR ancestry (Y-axis). The dotted 428 horizontal and vertical lines indicate $P < 2.5 \times 10^{-6}$ with a diagonal line for reference. Points are colored 429 based on which ancestry population the TWAS association meets P < 2.5×10^{-6} . (B) QQ-plot of TWAS 430 Z-scores, colored by meta-analytic strategies. Per ancestry refers to TWAS meta-analysis across meta-431 analyzed ancestry-specific GWAS summary statistics. Per bank/per ancestry refers to TWAS meta-432 433 analysis using all biobank- and ancestry-specific GWAS summary statistics. (C) Effect sizes and Bonferroni-corrected confidence intervals (CIs) for TWAS associations across 17 individual biobanks 434 (stratified by ancestry group with EUR in green and AFR in red) and 2 IVW meta-analysis strategies (in 435 yellow) for 5 representative genes. The Higgins-Thompson I² statistic for heterogeneity is provided, with 436 the dotted line showing the null. 437

438

Figure 4: *GReX-PheWAS* for categorizing phenome-wide associations for TAF7 genetically-regulated *expression in UKBB.* (A) Boxplots of -log₁₀ Benjamini-Hochberg FDR-adjusted P-values of GTAs across 9
phenotype groups. The dotted grey line showed FDR-adjusted P = 0.05. (B) Miami plot of TWAS Zscores (Y-axis) across phenotypes, colored by phecode group. The dotted grey line shows the
significance threshold for Benjamini-Hochberg FDR correction and phenotypes are labelled if the
association passes Bonferroni correction.

445

446 **STAR METHODS**

We first outline the steps of the TWAS pipeline employed for phenotype available for analysis in the
GBMI. Then, we provide details for the analyses presented in **Results**.

It is made available under a CC-BY 4.0 International license .

449

450 The GBMI TWAS Pipeline

451 Training expression models from genetics

Tissue-specific expression models trained with reference data from the Genotype-Tissue Expression 452 Project (GTEx) v8 (Aguet et al., 2020) are built using two methods: (1) Joint-Tissue Imputation (JTI), 453 which leverages shared genetic cis-regulation across tissues (Zhou et al., 2020), and (2) MOSTWAS, 454 455 which prioritizes tissue-specific distal-SNPs through rigorous mediation analysis to account for additional expression heritability (Bhattacharya et al., 2021a). Genes with significantly positive expression 456 heritability (nominal P < 0.05) and five-fold cross-validation (CV) adjusted $R^2 \ge 0.01$ with P < 0.05 are 457 considered for TWAS. Ancestry-specific models are trained, excluding SNPs with MAF < 0.01 and 458 deviated from Hardy-Weinberg at P < 10^{-5} across all 838 GTEx samples. The first iteration of the GBMI 459 TWAS pipeline focuses on EUR-ancestry models due to larger sample sizes. However, as sample sizes 460 for other ancestry groups increase, this pipeline can be adapted for these currently underrepresented 461 ancestries. In addition, models from other data sources using other methods can be incorporated in 462 463 subsequent steps.

464

465 Hypothesis tests for TWAS

To test for an association between tissue-specific GReX of a gene and a trait of interest, GWAS summary 466 statistics are integrated with these expression models. For the EUR-specific TWAS, we use EUR-specific 467 meta-analyzed GWAS summary statistics across all biobanks. JTI and MOSTWAS use two different 468 approaches to test for a GTA. For MR-JTI, the posterior predictive distribution of GReX is estimated, and 469 multiple-instrumental-variable causal inference is used to estimate the GTA, controlling for overall 470 heterogeneity (Zhou et al., 2020). For MOSTWAS, a weighted burden test is constructed, as in FUSION 471 (Bhattacharya et al., 2021a; Gusev et al., 2016; Pasaniuc et al., 2014). Both of these methods require a 472 LD reference panel; the GTEx LD matrix is used as a reference. Taken together, these methods provide 473 effect sizes, standard errors, Z-scores (effect sizes standardized by standard error), and P-values for 474 GTAs. A GTA is transcriptome-wide significant using a Bonferroni correction across all tests run. The 475 number of tests run is equal to the sum of the number of significant gene models across all tissues. 476

It is made available under a CC-BY 4.0 International license .

477

Follow-up tests and analyses are then run to provide context to the TWAS GTAs. A permutation test is 478 run by shuffling the SNP-gene weights 1,000 times and determining the TWAS Z-score at each 479 permutation, generating a null distribution. The original TWAS Z-score is compared to this null distribution 480 to generate a permutation P-value; Benjamini-Hochberg FDR correction is used to account for multiple 481 testing burden here. This test examines whether the SNP-gene relationship provides more information 482 483 than just the SNP-trait association. Next, for MOSTWAS, the distal-SNPs added-last test is run to measure the association from distal-SNPs in the expression models, conditional on the association from 484 485 local-SNPs (Bhattacharya et al., 2021a). This test prioritizes sets of mediating molecular features for the SNP-gene relationship with significant effects on the trait. Lastly, for genes whose models are built using 486 SNPs from overlapping genomic regions, probabilistic fine-mapping via FOCUS (default parameters and 487 priors) is employed to determine a 90% credible set of genes that explain the gene-level association 488 signal at the locus (Mancuso et al., 2019). FOCUS also outputs posterior inclusion probabilities for each 489 490 gene in the 90% credible set.

491

492 Analysis of ancestry-specific and -unaware models

To show the utility of ancestry-specific models, we train EUR- and AFR-specific models using elastic net 493 regression for 5 tissues with more than 70 samples from AFR ancestry patients: subcutaneous adipose 494 (N = 492 EUR, N = 71 AFR), tibial artery (N = 489 EUR, N = 76 AFR), skeletal muscle (N = 602 EUR), 495 N = 86 AFR), sun exposed lower leg skin (N = 518 EUR, N = 73 AFR), and whole blood (N = 574 EUR, 496 N = 80 AFR). To balance sample sizes in the imputation sample, we down-sampled the EUR ancestry 497 imputation sample to match the AFR imputation sample. We consider only genes with positive expression 498 heritability in both EUR and AFR training samples (Yang et al., 2011). We also build ancestry-unaware 499 models, where genotypes for EUR and AFR samples are pooled together in the training sample. We 500 calculate predictive performance in aligned and misaligned imputation samples based on ancestry; the 501 aligned imputation sample is one with ancestry that predominantly matches the ancestry of the training 502 sample. Predictive performance is measured with adjusted R² to account for sample size, using an 503 appropriate linear model between predicted and observed expression. For imputation samples that are 504

It is made available under a CC-BY 4.0 International license .

505	used in training (aligned imputation panel), we use leave-one-out CV when measuring predictive
506	performance. Lastly, when imputing into AFR and EUR samples using the ancestry-unaware models, we
507	use leave-one-out CV, as well, but only cross-validating over the AFR or EUR samples, respectively.
508	
509	Comparison of meta-analytic strategies
510	We compared 5 different meta-analytic strategies empirically: meta-analyzing across ancestry-specific,
511	per-biobank GWAS summary statistics using (1) inverse-variance weighting (IVW) and (2) sample-size
512	weighting (SSW), meta-analyzing across ancestry-specific meta-analyzed GWAS summary statistics
513	using (3) IVW and (4) SSW, and (5) TWAS using ancestry-unaware models into meta-analyzed GWAS
514	summary statistics across EUR and AFR ancestry groups. First, we consider three different sets of
515	GWAS summary statistics: biobank- and ancestry-specific summary statistics, ancestry-specific summary
516	statistics meta-analyzed across all biobanks, and summary statistics meta-analyzed across biobanks and
517	ancestry groups. In two former settings, for biobank <i>i</i> and a given gene, we generate $\beta_{_{TWAS,i}}$, the TWAS

effect size, and SE_{TWAS,i}, the corresponding standard error. Given B different biobanks, the IVW TWAS Z-

519 score, $Z_{TWAS,IVW}$, is calculated as:

520

$$Z_{TWAS,IVW} = \frac{\left(\frac{\sum_{i=1}^{B} \beta_{TWAS,i}/SE_{TWAS,i}}{\sum_{i=1}^{B} SE_{TWAS,i}}\right)}{\left(\sum_{i=1}^{B} SE_{TWAS,i}\right)^{1/2}}.$$

522

521

With $Z_{TWAS,i} = \beta_{TWAS,i}/SE_{TWAS,i}$ and N_i as the sample size of the *i*th biobank (or pooled sample size across all ancestry-specific biobank summary statistics), the SSW TWAS Z-score, $Z_{TWAS,SSW}$, is calculated as:

526

527
$$Z_{TWAS,SSW} = \frac{\sum_{i=1}^{B} N_i Z_{TWAS,i}}{\left(\sum_{i=1}^{B} N_i^2\right)^{1/2}}$$

528

529 For the ancestry-unaware TWAS, we use ancestry-unaware elastic net regression models and integrate 530 with GWAS summary statistics meta-analyzed across all ancestry groups and biobanks.

It is made available under a CC-BY 4.0 International license .

531

532 GReX-level phenome-wide association studies (GReX-PheWAS)

Transcriptome-wide significant genes are further prioritized by performing GReX-PheWAS to categorize 533 associations across a broad spectrum of phenotypes. Using UKBB summary statistics from European 534 ancestry patients (Bycroft et al., 2018), we tested for GTAs for 731 phenotypes grouped into 9 categories: 535 dermatologic, digestive, endocrine/metabolic, genitourinary, hematopoietic, musculoskeletal, neoplasms, 536 neurological, and respiratory. Here, we illustrate GReX-PheWAS using three genes from the European-537 specific TWAS for asthma risk using lung tissue expression: TAF7 (MOSTWAS model), IL18RAP (JTI 538 539 model), and TMEM258 (JTI model). A phenome-wide significant association was defined via Bonferroni correction (P < $\frac{0.05}{3 \times 731}$ = 2.28 × 10⁻⁵). 540

541

542 SUPPLEMENTAL INFORMATION

- Table S1: Difference in adjusted R² between models trained in aligned and misaligned ancestry samples
 as the ancestry of the imputation sample.
- 545 **Table S2:** *R*² of ancestry-specific models imputed into EUR imputation sample (training:imputation)
- 546 **Table S3**: *R*² of ancestry-specific models imputed into AFR imputation sample (training:imputation)
- 547 **Table S4**: Difference in R² between ancestry-specific and ancestry-unaware models across MAF
- 548 **Table S5**: Cross-validation R² of ancestry-unaware models across MAF threshold
- 549 **Table S6**: GReX-PheWAS results for 3 representative genes from asthma meta-analytic TWAS in
- 550 Europeans in GBMI that meet Bonferroni correction (P < 0.05/731)
- 551 **Figure S1:** Ratio of predictive performance of expression models in aligned versus misaligned imputation
- samples across AFR (left) and EUR (right) ancestry in the imputation sample. Here, we down-sample the
- 553 EUR imputation sample to match the sample size of the AFR imputation sample.
- **Figure S2**: Predictive performance of expression models in aligned and misaligned imputation samples.
- 555 **Figure S3**: Predictive performance of ancestry-unaware expression models compared to ancestry-
- specific models across 5 tissues. Boxplot of difference in predictive performance in EUR (A) and AFR (B)
- samples between ancestry-aligned models and ancestry-unaware models. We consider (1) individuals of

It is made available under a CC-BY 4.0 International license .

- all ancestry in the training sample of the ancestry-unaware model (gold) or only EUR and AFR individuals 558
- in the training sample (grey). The red line indicates a difference of 0. 559
- Figure S4: Predictive performance of ancestry-unaware expression models across minor allele frequency 560 thresholds. 561
- Figure S5: TWAS Miami plots across AFR and EUR ancestry groups for asthma using whole blood gene 562 expression models. 563
- 564 Figure S6: Correlation of TWAS Z-scores across ancestry-specific, individual biobank GWAS cohorts and 5 meta-analytic strategies. 565
- 566 Figure S7: TWAS associations across EUR and AFR ancestry groups for DFFA across 5 tissues. The
- effect size is given with the point (triangle if association is transcriptome-wide significant) with a 95% 567
- confidence interval provided. 568
- Figure S8: Miami plots of DFFA local-eQTLs and GWAS signal for SNPs around DFFA. In (A), color 569
- shows linkage disequilibrium R² to lead eQTL SNP. Grey line shows a nominal P-value cutoff of 0.05 (|Z| 570 571 = 1.96).
- Figure S9: Empirical Bayes estimates of bias and inflation in TWAS Z-scores across meta-analysis 572
- strategies. Estimates of bias (top) and bottom (inflation) with one standard error width around the 573
- estimate are given across meta-analysis strategies. The dotted lines provide a reference for the null (0 for 574 575 bias and 1 for inflation).
- Figure S10: Comparison of two IVW meta-analyzed Z-scores. Vertical and horizontal dotted lines give a 576
- reference for the Bonferroni-corrected threshold for transcriptome-significance. A diagonal line is provided 577 578 from reference.
- Figure S11: Comparison of meta-analyzed Z-scores with individual biobank TWAS Z-scores. Ancestry-579
- specific TWAS Z-scores for individual biobanks are shown in the top panel, colored by ancestry. Meta-580
- analyzed Z-scores are shown in the bottom panel with shapes reflecting the different strategies. Dotted 581
- 582 lines provide a reference for transcriptome-wide significance.
- Figure S12: UKBB T-PheWAS associations across 5 representative asthma-associated genes through 583
- European-only meta-analytic TWAS, grouped by phecode group. The horizontal dotted line shows FDR-584
- adjusted P = 0.05. 585

It is made available under a CC-BY 4.0 International license .

- 586 **Figure S13**: Miami plots of UKBB T-PheWAS associations across 2 genes previously implicated through
- 587 GWAS and detected in European-only meta-analytic TWAS in GBMI.

588

589 **REFERENCES**

Abul-Husn, N.S., and Kenny, E.E. (2019). Personalized Medicine and the Power of Electronic Health Records. Cell *177*, 58–69.

Aguet, F., Barbeira, A.N., Bonazzola, R., Brown, A., Castel, S.E., Jo, B., Kasela, S., Kim-Hellmuth, S.,
 Liang, Y., Oliva, M., et al. (2020). The GTEx Consortium atlas of genetic regulatory effects across human
 tissues. Science *369*, 1318–1330.

- Amariuta, T., Ishigaki, K., Sugishita, H., Ohta, T., Koido, M., Dey, K.K., Matsuda, K., Murakami, Y., Price,
- 596 A.L., Kawakami, E., et al. (2020). Improving the trans-ancestry portability of polygenic risk scores by 597 prioritizing variants in predicted cell-type-specific regulatory elements. Nature Genetics *52*, 1346–1354.
- Auton, A., Abecasis, G.R., Altshuler, D.M., Durbin, R.M., Bentley, D.R., Chakravarti, A., Clark, A.G.,
 Donnelly, P., Eichler, E.E., Flicek, P., et al. (2015). A global reference for human genetic variation. Nature
 526, 68–74.
- Baca, S., Singler, C., Zacharia, S., Seo, J.-H., Morova, T., Hach, F., Ding, Y., Schwarz, T., Flora Huang, C.-C., Kalita, C., et al. (2021). Genetic determinants of chromatin reveal prostate cancer risk mediated by
- 603 context-dependent gene regulation. BioRxiv 2021.05.10.443466.
- Baharian, S., Barakatt, M., Gignoux, C.R., Shringarpure, S., Errington, J., Blot, W.J., Bustamante, C.D.,
 Kenny, E.E., Williams, S.M., Aldrich, M.C., et al. (2016). The Great Migration and African-American
 Genomic Diversity. PLoS Genetics *12*, e1006059.
- Barbeira, A.N., Dickinson, S.P., Bonazzola, R., Zheng, J., Wheeler, H.E., Torres, J.M., Torstenson, E.S.,
 Shah, K.P., Garcia, T., Edwards, T.L., et al. (2018). Exploring the phenotypic consequences of tissue
 specific gene expression variation inferred from GWAS summary statistics. Nature Communications *9*, 1–
 20.
- Barfield, R., Feng, H., Gusev, A., Wu, L., Zheng, W., Pasaniuc, B., and Kraft, P. (2018). Transcriptomewide association studies accounting for colocalization using Egger regression. Genetic Epidemiology *42*, 418–433.
- Bhattacharya, A., García-Closas, M., Olshan, A.F., Perou, C.M., Troester, M.A., and Love, M.I. (2020). A
- framework for transcriptome-wide association studies in breast cancer in diverse study populations.Genome Biology *21*, 42.
- 617 Bhattacharya, A., Li, Y., and Love, M.I. (2021a). MOSTWAS: Multi-Omic Strategies for Transcriptome-618 Wide Association Studies. *17*, e1009398.
- Bhattacharya, A., Freedman, A.N., Avula, V., Harris, R., Liu, W., Pan, C., Lusis, A.J., Joseph, R.M.,
- Smeester, L., Hartwell, H.J., et al. (2021b). Genetic control of fetal placental genomics contributes to development of health and disease. MedRxiv 2021.04.12.21255170.
- Bhattacharya, S., Lou, X., Hwang, P., Rajashankar, K.R., Wang, X., Gustafsson, J.Å., Fletterick, R.J.,
- Jacobson, R.H., and Webb, P. (2014). Structural and functional insight into TAF1-TAF7, a subcomplex of transcription factor II D. Proceedings of the National Academy of Sciences of the United States of
- 625 America *111*, 9103–9108.

- Bycroft, C., Freeman, C., Petkova, D., Band, G., Elliott, L.T., Sharp, K., Motyer, A., Vukcevic, D.,
- Delaneau, O., O'Connell, J., et al. (2018). The UK Biobank resource with deep phenotyping and genomic data. Nature *562*, 203–209.
- 629 Cao, C., Ding, B., Li, Q., Kwok, D., Wu, J., and Long, Q. (2021). Power analysis of transcriptome-wide 630 association study: Implications for practical protocol choice. PLoS Genetics *17*, e1009405.
- Friedman, J., Hastie, T., and Tibshirani, R. (2010). Regularization Paths for Generalized Linear Models
 via Coordinate Descent. Journal of Statistical Software 33, 1–22.
- Gallagher, M.D., and Chen-Plotkin, A.S. (2018). The Post-GWAS Era: From Association to Function.
 American Journal of Human Genetics *102*, 717–730.
- Gamazon, E.R., Wheeler, H.E., Shah, K.P., Mozaffari, S. v, Aquino-Michaels, K., Carroll, R.J., Eyler, A.E.,
 Denny, J.C., Nicolae, D.L., Cox, N.J., et al. (2015). A gene-based association method for mapping traits
 using reference transcriptome data. Nature Genetics *47*, 1091–1098.
- Geoffroy, E., Gregga, I., and Wheeler, H.E. (2020). Population-Matched Transcriptome Prediction
 Increases TWAS Discovery and Replication Rate. IScience 23, 101850.
- Giambartolomei, C., Vukcevic, D., Schadt, E.E., Franke, L., Hingorani, A.D., Wallace, C., and Plagnol, V.
 (2014). Bayesian Test for Colocalisation between Pairs of Genetic Association Studies Using Summary
- 642 Statistics. PLoS Genetics 10, e1004383.
- Giambartolomei, C., Liu, J.Z., Zhang, W., Hauberg, M., Shi, H., Boocock, J., Pickrell, J., Jaffe, A.E.,
- Pasaniuc, B., and Roussos, P. (2018). A Bayesian framework for multiple trait colocalization from summary association statistics. Bioinformatics *34*, 2538–2545.
- Gleason, K.J., Yang, F., Pierce, B.L., He, X., and Chen, L.S. (2020). Primo: Integration of multiple GWAS
 and omics QTL summary statistics for elucidation of molecular mechanisms of trait-associated SNPs and
 detection of pleiotropy in complex traits. Genome Biology *21*, 236.
- Gusev, A., Ko, A., Shi, H., Bhatia, G., Chung, W., Penninx, B.W.J.H., Jansen, R., de Geus, E.J.C.,
 Boomsma, D.I., Wright, F.A., et al. (2016). Integrative approaches for large-scale transcriptome-wide
 association studies. Nature Genetics *48*, 245–252.
- Hauberg, M.E., Zhang, W., Giambartolomei, C., Franzén, O., Morris, D.L., Vyse, T.J., Ruusalepp, A.,
 Fromer, M., Sieberts, S.K., Johnson, J.S., et al. (2017). Large-Scale Identification of Common Trait and
- Disease Variants Affecting Gene Expression. American Journal of Human Genetics *100*, 885–894.
- He, X., Fuller, C.K., Song, Y., Meng, Q., Zhang, B., Yang, X., and Li, H. (2013). Sherlock: Detecting genedisease associations by matching patterns of expression QTL and GWAS. American Journal of Human
 Genetics *92*, 667–680.
- Hebbring, S.J. (2014). The challenges, advantages and future of phenome-wide association studies.
 Immunology *141*, 157–165.
- Hedges, L., and Vevea, J. (1998). Fixed- and random-effects models in meta-analysis. Psychological
 Methods *3*, 486–504.
- Higgins, J.P.T., and Thompson, S.G. (2002). Quantifying heterogeneity in a meta-analysis. Statistics in
 Medicine *21*, 1539–1558.
- Hu, Y., Li, M., Lu, Q., Weng, H., Wang, J., Zekavat, S.M., Yu, Z., Li, B., Gu, J., Muchnik, S., et al. (2019).
 A statistical framework for cross-tissue transcriptome-wide association analysis. Nature Genetics *51*,
- 666 **568–576**.

van Iterson, M., van Zwet, E.W., Heijmans, B.T., and Heijmans, B.T. (2017). Controlling bias and inflation
 in epigenome- and transcriptome-wide association studies using the empirical null distribution. Genome
 Biology *18*, 19.

- Johansson, Å., Rask-Andersen, M., Karlsson, T., and Ek, W.E. (2019). Genome-wide association
- analysis of 350 000 Caucasians from the UK Biobank identifies novel loci for asthma, hay fever and eczema. Human Molecular Genetics *28*, 4022–4041.
- Keys, K.L., Mak, A.C.Y., White, M.J., Eckalbar, W.L., Dahl, A.W., Mefford, J., Mikhaylova, A. v.,
- Contreras, M.G., Elhawary, J.R., Eng, C., et al. (2020). On the cross-population generalizability of gene
 expression prediction models. PLoS Genetics *16*, e1008927.
- Korthauer, K., Kimes, P.K., Duvallet, C., Reyes, A., Subramanian, A., Teng, M., Shukla, C., Alm, E.J., and
- Hicks, S.C. (2019). A practical guide to methods controlling false discoveries in computational biology.
 Genome Biology *20*, 1–21.
- Lee, C.H., Eskin, E., and Han, B. (2017). Increasing the power of meta-analysis of genome-wide
- association studies to detect heterogeneous effects. In Bioinformatics, (Oxford University Press), pp.
 i379–i388.
- Luningham, J.M., Chen, J., Tang, S., de Jager, P.L., Bennett, D.A., Buchman, A.S., and Yang, J. (2020).
 Bayesian Genome-wide TWAS Method to Leverage both cis- and trans-eQTL Information through
 Summary Statistics. American Journal of Human Genetics *107*, 714–726.
- Mancuso, N., Freund, M.K., Johnson, R., Shi, H., Kichaev, G., Gusev, A., and Pasaniuc, B. (2019).
 Probabilistic fine-mapping of transcriptome-wide association studies. Nature Genetics *51*, 675–682.
- Márquez-Luna, C., Gazal, S., Loh, P.R., Kim, S.S., Furlotte, N., Auton, A., and Price, A.L. (2020). LDpred funct: incorporating functional priors improves polygenic prediction accuracy in UK Biobank and 23andMe
 data sets. BioRxiv.
- Mbatchou, J., Barnard, L., Backman, J., Marcketta, A., Kosmicki, J.A., Ziyatdinov, A., Benner, C.,
- 691 O'Dushlaine, C., Barber, M., Boutkov, B., et al. (2020). Computationally efficient whole genome 692 regression for quantitative and binary traits. BioRxiv 2020.06.19.162354.
- McGuirl, M.R., Smith, S.P., Sandstede, B., and Ramachandran, S. (2020). Detecting shared genetic
 architecture among multiple phenotypes by hierarchical clustering of gene-level association statistics.
 Genetics *215*, 511–529.
- Nagpal, S., Meng, X., Epstein, M.P., Tsoi, L.C., Patrick, M., Gibson, G., de Jager, P.L., Bennett, D.A.,
 Wingo, A.P., Wingo, T.S., et al. (2019). TIGAR: An Improved Bayesian Tool for Transcriptomic Data
 Imputation Enhances Gene Mapping of Complex Traits. American Journal of Human Genetics *105*, 258–266.
- Pasaniuc, B., Zaitlen, N., Shi, H., Bhatia, G., Gusev, A., Pickrell, J., Hirschhorn, J., Strachan, D.P.,
- Patterson, N., Price, A.L., et al. (2014). Fast and accurate imputation of summary statistics enhances evidence of functional enrichment. Bioinformatics *30*, 2906–2914.
- Pathak, G.A., Singh, K., Miller-Fleming, T.W., Wendt, F., Ehsan, N., Hou, K., Johnson, R., Lu, Z.,
- Gopalan, S., Dimbou, L.Y., et al. (2020). Integrative analyses identify susceptibility genes underlying
 COVID-19 hospitalization. MedRxiv.
- Pavlides, J.M.W., Zhu, Z., Gratten, J., McRae, A.F., Wray, N.R., and Yang, J. (2016). Predicting gene targets from integrative analyses of summary data from GWAS and eQTL studies for 28 human complex
- traits. Genome Medicine *8*, 84.

- Portelli, M.A., Nicole Dijk, F., Ketelaar, M.E., Shrine, N., Hankinson, J., Bhaker, S., Grotenboer, N.S.,
- Obeidat, M., Henry, A.P., Billington, C.K., et al. (2020). Phenotypic and functional translation of IL1RL1
- locus polymorphisms in lung tissue and asthmatic airway epithelium. JCI Insight 5.
- Reijmerink, N.E., Postma, D.S., Bruinenberg, M., Nolte, I.M., Meyers, D.A., Bleecker, E.R., and
- Koppelman, G.H. (2008). Association of IL1RL1, IL18R1, and IL18RAP gene cluster polymorphisms with asthma and atopy. Journal of Allergy and Clinical Immunology *122*, 651-654.e8.
- Reijmerink, N.E., Postma, D.S., and Koppelman, G.H. (2010). The candidate gene approach in asthma:
 what happens with the neighbours? European Journal of Human Genetics 17.
- 717 Shang, L., Smith, J.A., Zhao, W., Kho, M., Turner, S.T., Mosley, T.H., Kardia, S.L.R., and Zhou, X.
- (2020). Genetic Architecture of Gene Expression in European and African Americans: An eQTL Mapping
 Study in GENOA. American Journal of Human Genetics *106*, 496–512.
- Shi, J., and Lee, S. (2016). A novel random effect model for GWAS meta-analysis and its application to
 trans-ethnic meta-analysis. Biometrics 72, 945–954.
- Shifman, S., Kuypers, J., Kokoris, M., Yakir, B., and Darvasi, A. (2003). Linkage disequilibrium patterns of
 the human genome across populations. Human Molecular Genetics *12*, 771–776.
- 524 Smith, G.D., and Ebrahim, S. (2003). 'Mendelian randomization': can genetic epidemiology contribute to 525 understanding environmental determinants of disease? International Journal of Epidemiology *32*, 1–22.
- Stevens, J.R., Masud, A. al, and Suyundikov, A. (2017). A comparison of multiple testing adjustment
 methods with block-correlation positivelydependent tests. PLoS ONE *12*.
- Swede, H., Stone, C.L., and Norwood, A.R. (2007). National population-based biobanks for genetic
 research. Genetics in Medicine *9*, 141–149.
- Unlu, G., Gamazon, E.R., Qi, X., Levic, D.S., Bastarache, L., Denny, J.C., Roden, D.M., Mayzus, I.,
- Breyer, M., Zhong, X., et al. (2019). GRIK5 Genetically Regulated Expression Associated with Eye and
- 732 Vascular Phenomes: Discovery through Iteration among Biobanks, Electronic Health Records, and
- Zebrafish. The American Journal of Human Genetics *104*, 503–519.
- Unlu, G., Qi, X., Gamazon, E.R., Melville, D.B., Patel, N., Rushing, A.R., Hashem, M., Al-Faifi, A., Chen,
 R., Li, B., et al. (2020). Phenome-based approach identifies RIC1 -linked Mendelian syndrome through
 zebrafish models, biobank associations and clinical studies. Nature Medicine 2020 26:1 26, 98–109.
- 737 Veturi, Y., and Ritchie, M.D. (2018). How powerful are summary-based methods for identifying
- expression-trait associations under different genetic architectures? In Pacific Symposium on
 Biocomputing, (World Scientific Publishing Co. Pte Ltd), pp. 228–239.
- Vicente, C.T., Revez, J.A., and Ferreira, M.A.R. (2017). Lessons from ten years of genome-wide association studies of asthma. Clinical and Translational Immunology *6*, e165.
- Wainberg, M., Sinnott-Armstrong, N., Mancuso, N., Barbeira, A.N., Knowles, D.A., Golan, D., Ermel, R.,
 Ruusalepp, A., Quertermous, T., Hao, K., et al. (2019). Opportunities and challenges for transcriptome-
- vide association studies. Nature Genetics *51*, 592–599.
- 745 Wei, W.Q., Bastarache, L.A., Carroll, R.J., Marlo, J.E., Osterman, T.J., Gamazon, E.R., Cox, N.J., Roden,
- D.M., and Denny, J.C. (2017). Evaluating phecodes, clinical classification software, and ICD-9-CM codes for phenome-wide association studies in the electronic health record. PLoS ONE *12*.
- Wijmenga, C., and Zhernakova, A. (2018). The importance of cohort studies in the post-GWAS era.
 Nature Genetics *50*, 322–328.

- 750 Wyss, A.B., Sofer, T., Lee, M.K., Terzikhan, N., Nguyen, J.N., Lahousse, L., Latourelle, J.C., Smith, A.V.,
- Bartz, T.M., Feitosa, M.F., et al. (2018). Multiethnic meta-analysis identifies ancestry-specific and crossancestry loci for pulmonary function. Nature Communications *9*, 1–15.
- Yang, F., Wang, J., Pierce, B.L., and Chen, L.S. (2017). Identifying cis-mediators for trans-eQTLs across
 many human tissues using genomic mediation analysis. Genome Research 27, 1859–1871.
- Yang, J., Lee, S.H., Goddard, M.E., and Visscher, P.M. (2011). GCTA: a tool for genome-wide complex
 trait analysis. American Journal of Human Genetics *88*, 76–82.
- Yuan, Z., Zhu, H., Zeng, P., Yang, S., Sun, S., Yang, C., Liu, J., and Zhou, X. (2020). Testing and
 controlling for horizontal pleiotropy with probabilistic Mendelian randomization in transcriptome-wide
 association studies. Nature Communications *11*, 1–14.
- Zhang, Y., Quick, C., Yu, K., Barbeira, A., Luca, F., Pique-Regi, R., Kyung Im, H., and Wen, X. (2020).
 PTWAS: Investigating tissue-relevant causal molecular mechanisms of complex traits using probabilistic
 TWAS analysis. Genome Biology *21*, 1–26.
- Zhong, Y., Perera, M.A., and Gamazon, E.R. (2019). On Using Local Ancestry to Characterize the
- Genetic Architecture of Human Traits: Genetic Regulation of Gene Expression in Multiethnic or Admixed
 Populations. American Journal of Human Genetics *104*, 1097–1115.
- Zhou, D., Jiang, Y., Zhong, X., Cox, N.J., Liu, C., and Gamazon, E.R. (2020). A unified framework for
 joint-tissue transcriptome-wide association and Mendelian randomization analysis. Nature Genetics *52*,
 1239–1246.
- Zhou, W., Nielsen, J.B., Fritsche, L.G., Dey, R., Gabrielsen, M.E., Wolford, B.N., LeFaive, J., VandeHaar,
 P., Gagliano, S.A., Gifford, A., et al. (2018). Efficiently controlling for case-control imbalance and sample
- relatedness in large-scale genetic association studies. Nature Genetics 50, 1335–1341.
- Zhou, W., Kanai, M., Wu, K.-H.H., Humaira, R., Tsuo, K., Hirbo, J.B., Wang, Y., Bhattacharya, A., Zhao,
 H., Namba, S., et al. (2021). Global Biobank Meta-analysis Initiative: powering genetic discovery across
 human diseases. MedRxiv 27, 2021.11.19.21266436.
- Zhu, A., Matoba, N., Wilson, E.P., Tapia, A.L., Li, Y., Ibrahim, J.G., Stein, J.L., and Love, M.I. (2021).
- MRLocus: Identifying causal genes mediating a trait through Bayesian estimation of allelic heterogeneity.
 PLOS Genetics *17*, e1009455.
- Zhu, Z., Guo, Y., Shi, H., Liu, C.L., Panganiban, R.A., Chung, W., O'Connor, L.J., Himes, B.E., Gazal, S.,
 Hasegawa, K., et al. (2020). Shared genetic and experimental links between obesity-related traits and
- asthma subtypes in UK Biobank. Journal of Allergy and Clinical Immunology 145, 537–549.

It is made available under a CC-BY 4.0 International license .




Figure 1: Overview of GBMI transcriptome-wide association study (TWAS) pipeline with challenges at every data level. **(A)** Each level of data in TWAS introduces a unique set of challenges: (1) genetics data include confounding from genetic ancestry, population structure and relatedness, and complex linkage disequilibrium patterns, (2) gene expression data introduces context-specific factors, such as tissue-, cell-type-, or cell-state-specific expression, and (3) phenotypic data, especially in the meta-analyses of multiple biobanks, involve challenges in acquiring and aggregating phenotypes, properly defining controls for phenotypes, and ascertainment and selection bias from non-random sampling. **(B)** An overview of the GBMI TWAS pipeline: (1) JTI and MOSTWAS for model training, (2) inverse-variance weighted meta-analysis using per-biobank, per-ancestry group TWAS summary statistics, and (3) various follow-up tests, including conditional or permutation tests, distal-SNPs added last test, probabilistic fine-mapping using FOCUS, and tests for SNP horizontal pleiotropy. Dotted lines represent associations that are tested in the TWAS pipeline, while the solid lines represent a link built through predictive modeling.

It is made available under a CC-BY 4.0 International license .




Figure 2: Comparison of predictive performance of genetic models of expression across ancestry. **(A)** Distribution of difference in adjusted R² (Y-axis) when predicting expression in the AFR imputation sample between models trained in EUR and in AFR training samples across tissue (X-axis). **(B)** Distribution of difference in adjusted R² between ancestry-specific and ancestry-unaware models imputing into EUR (left) and AFR (right) samples.

It is made available under a CC-BY 4.0 International license .





Figure 3: Comparison of meta-analytic strategies for multi-biobank, trans-ancestry TWAS. **(A)** Scatterplot of per-ancestry meta-analyzed TWAS scores across EUR (X-axis) and AFR ancestry (Y-axis). The dotted horizontal and vertical lines indicate $P < 2.5 \times 10^{-6}$ with a diagonal line for reference. Points are colored based on which ancestry population the TWAS association meets $P < 2.5 \times 10^{-6}$. **(B)** QQ-plot of TWAS Z-scores, colored by meta-analytic strategies. Per ancestry refers to TWAS meta-analysis across meta-analyzed ancestry-specific GWAS summary statistics. Per bank/per ancestry refers to TWAS meta-analysis using all biobank- and ancestry-specific GWAS summary statistics. **(C)** Effect sizes and Bonferroni-corrected confidence intervals (CIs) for TWAS associations across 17 individual biobanks (stratified by ancestry group with EUR in green and AFR in red) and 2 IVW meta-analysis strategies (in yellow) for 5 representative genes. The Higgins-Thompson I² statistic for heterogeneity is provided, with the dotted line showing the null.





Phecode

Figure 4: *GReX-PheWAS* for categorizing phenome-wide associations for TAF7 genetically-regulated expression in UKBB. **(A)** Boxplots of -log₁₀ Benjamini-Hochberg FDR-adjusted P-values of GTAs across 9 phenotype groups. The dotted grey line showed FDR-adjusted P = 0.05. **(B)** Miami plot of TWAS Z-scores (Y-axis) across phenotypes, colored by phecode group. The dotted grey line shows the significance threshold for Benjamini-Hochberg FDR correction and phenotypes are labelled if the association passes Bonferroni correction.